Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?
Anna Alisi, Sara Tomaselli, Clara Balsano, Angela Gallo – 11 May 2011
Carcinogen‐induced hepatic tumors in KLF6+/− mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation
Mirko Tarocchi, Rebekka Hannivoort, Yujin Hoshida, Ursula E. Lee, Diana Vetter, Goutham Narla, Augusto Villanueva, Moshe Oren, Josep M. Llovet, Scott L. Friedman – 11 May 2011 – Inactivation of KLF6 is common in hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) infection, thereby abrogating its normal antiproliferative activity in liver cells. The aim of the study was to evaluate the impact of KLF6 depletion on human HCC and experimental hepatocarcinogenesis in vivo.
Mechanisms by which TLR4 and endotoxin promote hepatocellular carcinoma require further investigation
Ali Mencin, Geum‐Youn Gwak, Robert F. Schwabe – 11 May 2011
Liver transplantation in human immunodeficiency virus‐positive patients
Deepak Joshi, John O'Grady, Chris Taylor, Nigel Heaton, Kosh Agarwal – 11 May 2011 – With the successful introduction of combined antiretroviral therapy (cART), human immunodeficiency virus (HIV) is now regarded as a chronic illness with excellent long‐term outcomes. However, chronic exposure to viral etiologies (ie, chronic hepatitis B and hepatitis C) and drug‐induced toxicity secondary to cART have resulted in increasing rates of mortality and morbidity due to end‐stage liver disease.
Reply:
Anna S. Lok, James E. Everhart – 11 May 2011
Toll‐like receptor 2 polymorphism and gram‐positive bacterial infections after liver transplantation
Sang‐Oh Lee, Robert A. Brown, Seung H. Kang, Rima C. Abdel‐Massih, Raymund R. Razonable – 11 May 2011 – Toll‐like receptor 2 (TLR2) is an immune sensor for gram‐positive bacterial cell wall components. Single‐nucleotide polymorphisms (SNPs) in the TLR2 gene that impair its function may, therefore, influence the risk and outcomes of gram‐positive bacterial infections.
Should we perform deceased donor liver transplantation after living donor liver transplantation has failed?
Paul D. Greig, Andreas Geier, Anthony M. D'Alessandro, Michael Campbell, Linda Wright – 11 May 2011
Overdose with suicidal intent: Ethical considerations for liver transplant programs
Rosamond Rhodes, Sourabh Aggarwal, Thomas D. Schiano – 11 May 2011 – Liver transplantation (LT) programs encounter patients with fulminant hepatic failure resulting from suicide attempts involving acetaminophen or multidrug ingestion. Members of transplant teams often have different opinions about whether these patients should be offered transplantation. Disagreements can delay the transfer of these patients to a transplant facility and negatively affect their management.
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
Roeland Zoutendijk, Jurriën G. P. Reijnders, Ashley Brown, Fabien Zoulim, David Mutimer, Katja Deterding, Jörg Petersen, Wolf Peter Hofmann, Maria Buti, Teresa Santantonio, Florian van Bömmel, Pierre Pradat, Ye Oo, Marc Luetgehetmann, Thomas Berg, Bettina E. Hansen, Heiner Wedemeyer, Harry L. A. Janssen, for the VIRGIL Surveillance Study Group – 11 May 2011 – Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)‐naïve chronic hepatitis B (CHB) patients.